Recent searches
Search options
Administered by:
Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee - Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- t... - https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee?utm_source=rss1.0mainlinkanon&utm_medium=feed #medicine
science.slashdot.orgNovo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee - SlashdotPharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a...